TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Medicare/Medicaid MMM
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Copyright/Patent/Trademark CPT
S. 150/H.R. 9070, the Affordable Prescriptions for Patients Act of 2023, and related House legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Health Issues HCR
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Pharmacy PHA
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Taxation/Internal Revenue Code TAX
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.